Pharmacogenetics of antihypertensive drug response

Current Hypertension Reports

Volumn 6, Issue 1, 2004, Pages 15-20

  Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADDUCIN; ALDOSTERONE SYNTHASE; ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN;

ADRENERGIC RECEPTOR BLOCKING; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; ESSENTIAL HYPERTENSION; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NONHUMAN; PHARMACOGENETICS; PILOT STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM ABSORPTION;

EID: 5444220883     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0005-9     Document Type: Review

References (30)

1. Bianchi G, Staessen JA, Patrizia F: Pharmacogenomics of primary hypertension: the lessons from the past to look toward the future. Pharmacogenomics 2003, 4:279-296.
2. Cadman PE, O'Connor DT: Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens 2003, 12:61-70.
3. Laragh JH, Lamport B, Sealey J, Alderman MH: Diagnosis ex juvantibus: individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988, 12: 223-226.
4. Barlassina C, Lanzani C, Manunta P, Bianchi G: Genetics of essential hypertension: from families to genes. J Am Soc Nephrol 2002, 13(Suppl3):S155-S164.
5. Lindpaintner K: Pharmacogenetics and the future of medical practice. J Mol Med 2003, 81:141-153.
6. Lifton RP, Wilson FH, Choate KA, Geller DS: Salt and blood pressure: new insight from human genetic studies. Cold Spring Harb Symp Quant Biol 2002, 67:445-450.
7. Siragy HM: ALLHAT: Do we have all the answers yet? Curr Hypertens Rep 2003, 5:293-294.
8. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST: Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 2002, 61:1047-1055.
9. Sciarrone MT, Stella P, Barlassina C, et al.: ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003, 41:398-403.
10. Bianchi G, Tripodi G: Genetics of hypertension: the adducin paradigm. Ann N Y Acad Sci 2003, 986:660-668.
11. Rigat B, Hubert C, Alhenc-Gelas F, et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
12. Lindpaintner K, Pfeffer MA, Kreutz R, et al.: A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995, 332:706-711.
13. Singer DR, Missouris CG, Jeffery S: Angiotensin-converting enzyme gene polymorphism: what to do about all the confusion. Circulation 1996, 94:236-239.
14. Costerousse O, Allegrini J, Huang W, Alhenc-Gelas F: Angiotensin I-converting enzyme (kininase II) in cardiovascular and renal regulations and diseases. Biol Res 1998, 31:161-167.
15. Barlassina C, Schork NJ, Manunta P, et al.: Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Int 2000, 57:1083-1090.
16. Swart S, Bing RF, Swales JD, Thurston H: Plasma renin in long-term diuretic treatment of hypertension: effect of discontinuation and restarting therapy. Clin Sci (Lond) 1982, 63: 121-125.
17. Cusi D, Barlassina C, Azzani T, et al.: Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997, 349:1353-1357.
18. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E: Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002, 62:1718-1723.
19. Psaty BM, Smith NL, Heckbert SR, et al.: Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002, 287:1680-1689.
20. Malmqvist K, Kahan T, Edner M, et al.: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001, 19:1167-1176.
21. Kurland L, Melhus H, Karlsson J, et al.: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type I antagonist treatment in hypertensive patients. J Hypertens 2001, 19:1783-1787.
22. Kurland L, Melhus H, Karlsson J, et al.: Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002, 15:389-393.
23. Bassett MH, Zhang Y, Clyne C, et al.: Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1. J Mol Endocrinol 2002, 28: 125-135.
24. Kurland L, Melhus H, Karlsson J, et al.: Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002, 20:657-663.
25. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41-46.
26. Schmieder RE, Erdmann J, Delles C, et al.: Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol 2001, 37: 175-182.
27. Siegel AK, Planert M, Rademacher S, et al.: Genetic loci contribute to the progression of vascular and cardiac hypertrophy in salt-sensitive spontaneous hypertension. Arterioscler Thromb Vasc Biol 2003, 23:1211-1217.
28. Liljedahl U, Karlsson J, Melhus H, et al.: A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003, 13:7-17.
29. Singh BM, Mehta JL: Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 2003, 163:1296-1304.
30. Terwilliger JD, Haghighi F, Hiekkalinna TS, Goring HH: A biased assessment of the use of SNPs in human complex traits. Curr Opin Genet Dev 2002, 12:726-734.